By Fineline Cube 
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19% year-over-year (YOY) to USD 3.6 billion and non-GAAP net income rising 12% to USD 1.04 billion. The strong performance was driven by successful product transitions, robust collaboration revenue from Sanofi, and the recent FDA approval of its first gene therapy under the Commissioner’s National Priority Voucher program.
Financial Highlights – Q1 2026
| Metric | Q1 2026 | YOY Change |
|---|---|---|
| Total Revenues | USD 3.6 billion | +19% |
| Non-GAAP Net Income | USD 1.04 billion | +12% |
| Sanofi Collaboration Revenue | USD 1.451 billion | Significant increase due to higher profit share |
| R&D Investment | Not specified in announcement | Consistent with innovation-focused strategy |
Product Portfolio Performance
EYLEA Franchise Transition
- EYLEA HD (aflibercept): Net product sales surged 52% YOY to USD 468 million, demonstrating rapid market adoption
- Original EYLEA: Sales declined 36% to USD 473 million, reflecting successful patient transition to the high-dose formulation
- Strategic Impact: Portfolio optimization maintaining overall franchise strength while extending patent protection timeline
Immuno-Oncology Growth
- Libtayo (cemiplimab): Global sales reached USD 438 million, representing 54% YOY growth across multiple indications including NSCLC, CSCC, and BCC
Gene Therapy Milestone
- Otarmeni (lunsotogene parvec): Received accelerated FDA approval in April 2026 as the first gene therapy approved under the Commissioner’s National Priority Voucher (CNPV) program
- Significance: Establishes Regeneron’s entry into the gene therapy space with regulatory precedent-setting approval pathway
Sanofi Collaboration Strength
| Aspect | Detail |
|---|---|
| Q1 Collaboration Revenue | USD 1.451 billion |
| Profit Share Adjustment | Increased company share of antibody commercialization profits |
| Dupixent Performance | Global net sales (Sanofi-reported) increased 33% to USD 4.9 billion |
| Therapeutic Areas | Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis |
| Strategic Value | Collaboration remains cornerstone of Regeneron’s revenue diversification strategy |
Market Implications & Strategic Outlook
- Portfolio Diversification: Successful management of EYLEA lifecycle transition demonstrates strategic planning for patent cliff mitigation
- Innovation Pipeline: Otarmeni approval validates Regeneron’s expansion beyond traditional biologics into advanced therapy modalities
- Financial Resilience: Strong collaboration revenue provides stable cash flow to fund internal R&D investments across multiple therapeutic areas
- Competitive Positioning: EYLEA HD’s rapid adoption suggests effective physician education and payer acceptance strategies
- Growth Trajectory: Continued double-digit growth across key franchises positions Regeneron for sustained market leadership in ophthalmology and immunology
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product adoption rates, and strategic initiatives. Actual results may differ due to risks including competitive pressures, regulatory developments, and market dynamics affecting pharmaceutical pricing and reimbursement.-Fineline Info & Tech